Latest Us Market Expansion News

Orthocell has secured a strategic foothold in Thailand's $84 million nerve repair sector by appointing MediTime as exclusive Remplir distributor, leveraging established clinical networks to accelerate market penetration.

Cyclopharm Limited delivered a record $17.1 million in revenue for 1H FY26, driven by a 73% surge in US Technegas® sales. However, delays in clinical guideline publication have pushed the short-term US installation target beyond 2026, while medium-term ambitions remain intact.

Smart Parking (ASX:SPZ) has acquired American Parking, adding 54 sites across Oklahoma, Texas, and Arkansas and boosting its US portfolio to over 200 locations. The $12 million deal is expected to be earnings accretive and supports the rollout of SmartCloud technology.

Jindalee Lithium has completed a A$2.4 million entitlement offer, issuing over 5.2 million shares with attaching options to fund its McDermitt Lithium Project and support a NASDAQ listing.

LTR Pharma has confirmed it disclosed a binding US commercialisation agreement for ROXUS promptly after signing, responding to ASX scrutiny over pre-announcement trading activity.

Hydralyte USA secures A$392,000 through a share placement, appoints two new non-executive directors, and implements significant cost reductions following CEO resignation as it targets cash-flow break-even and strategic expansion.

Vitrafy Life Sciences has secured A$30 million through an institutional placement to ramp up manufacturing of its Guardion cryopreservation devices and expand US sales operations, with an additional A$2 million sought via a shareholder plan.

Control Bionics advances its neural-signal technology across assistive communication, sports, and medical sectors, securing key US reimbursement and distribution agreements while broadening its international footprint.

Optiscan and Mayo Clinic have completed all key engineering milestones in their two-year partnership to develop a digital endomicroscopic imaging system for robotic surgery, extending their agreement to support further clinical and commercial planning.

4DMedical has landed a three-year commercial contract with SimonMed Imaging, deploying its CT:VQ™ technology across more than 170 US outpatient centres, marking a significant step in its US market expansion.

Bubs Australia expects FY26 revenue between $105 million and $115 million, with underlying EBITDA forecast at $4 million to $8 million despite external challenges including regulatory delays and increased air freight costs.

PainChek has secured A$5.5 million via convertible notes to accelerate its US sales expansion and strengthen working capital amid key commercial milestones.